Bromocriptine

Bromocriptine
Clinical data
Trade names	Parlodel, others
Other names	2-Bromoergocriptine; Bromoergocryptine; 2-Bromocriptine; CB-154
AHFS/Drugs.com	Monograph
MedlinePlus	a682079
Pregnancy; category	AU: A; ;
Routes of; administration	Oral, vaginal, intravenous
Drug class	Dopamine receptor agonist; Serotonin receptor agonist; Adrenergic receptor modulator; Antiparkinsonian agent; Prolactin inhibitor; Anti-diabetic drug
ATC code	G02CB01 (WHO) N04BC01 (WHO);
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	28% of oral dose absorbed
Metabolism	Extensively liver-mediated
Elimination half-life	12–14 hours
Excretion	85% bile (feces), 2.5–5.5% urine
Identifiers
	IUPAC name (5′α)-2-bromo-12′-hydroxy-5′-(2-methylpropyl)-3′,6′,18-trioxo-2′-(propan-2-yl)ergotaman;
CAS Number	25614-03-3 ;
PubChem CID	31101;
IUPHAR/BPS	35;
DrugBank	DB01200 ;
ChemSpider	28858 ;
UNII	3A64E3G5ZO;
KEGG	D03165 ;
ChEBI	CHEBI:3181 ;
ChEMBL	ChEMBL493 ;
CompTox Dashboard (EPA)	DTXSID1022687 ;
ECHA InfoCard	100.042.829
Chemical and physical data
Formula	C32H40BrN5O5
Molar mass	654.606 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES BrC1=C(C[C@H]2N(C)C3)C4=C(C=CC=C4C2=C[C@H]3C(N[C@]5(C(C)C)O[C@@]6(N([C@@H](CC(C)C)C(N7CCC[C@H]76)=O)C5=O)O)=O)N1;
	InChI InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1 ; Key:OZVBMTJYIDMWIL-AYFBDAFISA-N ;
	(verify)

Bromocriptine, sold under the brand name Parlodel among others, is an ergoline derivative and dopamine agonist that is used in the treatment of pituitary tumors, Parkinson's disease, hyperprolactinaemia, neuroleptic malignant syndrome, and, as an adjunct, type 2 diabetes.

It was patented in 1968 and approved for medical use in 1975.